Advanced Medical Solutions Group plc (AMS), the UK-based wound care and surgical specialties manufacturer, has disclosed a major shareholding change after Société Générale reduced its voting interest in the company. A TR-1 regulatory notification published on 16 November 2026 reveals that the French banking group's total position fell from 5.108209% to 3.929347% of voting rights, crossing below the 5% reportable threshold. The change was triggered on 9 November 2026, with the issuer notified the following day, and represents a disposal of 8,689,409 direct voting rights remaining in AMS.
Key Points
- Advanced Medical Solutions Group plc (AMS), ISIN GB0004536594
- Société Générale's voting stake in AMS fell from 5.108209% to 3.929347%, crossing below the 5% major holding threshold
- Threshold crossed on 9 November 2026; issuer notified 10 November 2026; notification completed in London
- Investors may be watching whether further disposals by institutional shareholders alter the company's major holder register
Société Générale's AMS Voting Rights Drop to 3.929347% After November Disposal
According to the TR-1 standard notification form, Société Générale, registered in London, United Kingdom, held 8,689,409 direct voting rights in Advanced Medical Solutions Group as of 9 November 2026, equating to 3.929347% of total voting rights. The previous notification recorded a position of 5.108209%, meaning the disposal reduced the bank's holding by approximately 1.179 percentage points. The notification confirms the movement relates entirely to voting rights attached to shares, with no financial instruments such as options or contracts for difference forming any part of the position. Société Générale is noted as not being controlled by any natural person or legal entity in connection with this holding.
What the Sub-5% Crossing Means Under UK DTR Disclosure Rules
Under the UK Financial Conduct Authority's Disclosure Guidance and Transparency Rules (DTR5), major shareholders must notify an issuer whenever their voting rights cross certain percentage thresholds, including 5%. The trigger date of 9 November 2026 therefore confirms that Société Générale's holding moved through this statutory level as a result of a disposal of voting rights. The notification was completed in London on 10 November 2026. All 8,689,409 voting rights disclosed are classified as direct holdings under DTR5.1, with zero indirect rights and zero rights through financial instruments recorded in sections 8B1 or 8B2 of the form.
Advanced Medical Solutions Group: Wound Care Specialist With Broad European Footprint
Advanced Medical Solutions Group is a UK-listed medical device company focused on the development and manufacture of wound care and wound closure products, including surgical sealants, haemostats, and advanced wound dressings. The company operates across multiple international markets and supplies healthcare providers and distributors globally. Changes in the composition of the institutional shareholder register, such as this movement by a significant European banking group, can be a point of focus for investors monitoring liquidity and institutional sentiment towards the company's strategic progress and product portfolio development.



Please wait processing your request...